Pharma's Big Defeat: US Rebate Proposal Hits The End Of The Road
White House will not move forward with a rebate proposal the drug industry supported as a way to lower patient drug spending.
You may also be interested in...
Sanofi said the aggregate US net price of its drugs declined by 11.1% in 2019, while list prices increased 2.9%.
A lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors, but industry is confidently executing on focused strategies as it welcomes a new decade. The persistent overhang is US drug pricing and political uncertainty.
Industry CEOs expressed reservations about the US drug pricing legislation in the Senate, but said they support reforms that will impact patient affordability, during Q2 calls.